In addition, DEX reduced in vitro TOP2A levels and the accumulation of DOX-induced DSB in fibrosarcoma-derived cells but not in lung cancer cells, thereby highlighting the inconsistency of DEX in interfering with the anticancer effects of DOX as was also observed in the current study. Here, TOP2A is linked to lung cancer.